Mantle cell lymphoma: Observation to transplantation

Therapeutic Advances in Hematology

Volumn 6, Issue 1, 2015, Pages 37-48

  Rajabi, Babak ^a   Sweetenham, John W ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

chemo immunotherapy; ibrutinib; mantle cell lymphoma; transplantation

Indexed keywords

EID: 84993725154     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714561579     Document Type: Review

References (82)

1. Andersen N. Pedersen L. Elonen E. Johnson A. Kolstad A. Franssila K. et al. (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 71: 73–80.
2. Ansell S. Inwards D. Rowland K. Flynn P. Morton R. Moore D. Jr et al. (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113: 508–514.
3. Armand P. Kim H. Ho V. Cutler C. Koreth J. Antin J. et al. (2008) Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 14: 418–425.
4. Bernstein S. Epner E. Unger J. Leblanc M. Cebula E. Burack R. et al. (2013) A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 24: 1587–1593.
5. Brepoels L. Stroobants S. de Wever W. Dierickx D. Vandenberghe P. Thoma J. et al. (2008) Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 49: 1693–1701.
6. Carvajal-Cuenca A. Sua L. Pittaluga S. Royo C. Song J. Sargent R. et al. (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97: 270–278.
7. Chang J. Peterson C. Choi S. Eickhoff J. Kim K. Yang D. et al. (2011) VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 155: 190–197.
8. Cook G. Smith G. Kirkland K. Lee J. Pearce R. Thomson K. et al. (2010) Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for blood and marrow transplantation. Biol Blood Marrow Transplant 16: 1419–1427.
9. Corradini P. Dodero A. Farina L. Fanin R. Patriarca F. Miceli R. et al. (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome. Leukemia 21: 2316–2323.
10. Delarue R. Haioun C. Ribrag V. Brice P. Delmer A. Tilly H. et al. (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 121: 48–53.
11. Determann O. Hoster E. Ott G. Wolfram Bernd H. Loddenkemper C. Leo Hansmann M. et al. (2008) Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111: 2385–2387.
12. Dictor M. Ek S. Sundberg M. Warenholt J. Gyorgy C. Sernbo S. et al. (2009) Strong lymphoid nuclear expression of SOX 11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 94: 1563–1568.
13. Dreyling M. Lenz G. Hoster E. van Hoof A. Gisselbrecht C. Schmits R. et al. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105: 2677–2684.
14. Ek S. Dictor M. Jerkeman M. Jirstrom K. Jirström K. Borrebaeck C. et al. (2008) Nuclear expression of the non B-cell lineage Sox 11 transcription factor identifies mantle cell lymphoma. Blood 111: 800–805.
15. Eve H. Carey S. Richardson S. Heise C. Mamidipudi V. Shi T. et al. (2012) Single agent lenalidomide in relapsed / refractory mantle cell lymphoma: Results from a UK phase II study suggest activity and possible gender differences. BR J Haematol 159: 154–163.
16. Eve H. Furtado M. Hamon M. Rule S. (2009) Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 27: e189–e190.
17. Evens A. Winter J. Hou N. Nelson B. Rademaker A. Patton D. et al. (2008) A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 140: 385–393.
18. Fernandez V. Salamero O. Espinet B. Solé F. Royo C. Navarro A. et al. (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70: 1408–1418.
19. Ferrer A. Bosch F. Villamor N. Rozman M. Graus F. Gutiérrez G. et al. (2008) Central nervous system involvement in mantle cell lymphoma. Ann Oncol 19: 135–141.
20. Fisher R. Bernstein S. Kahl B. Djulbegovic B. Robertson M. de Vos S. et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867–4874.
21. Forstpointner R. Unterhalt M. Dreyling M. Böck H. Repp R. Wandt H. et al. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003–4008.
22. Friedberg J. Vose J. Kelly J. Young F. Bernstein S. Peterson D. et al. (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed / refractory indolent and mantle cell lymphoma. Blood 117: 2807–2812.
23. Geisler C. Kolstad A. Laurell A. Andersen N. Pedersen L. Jerkeman M. et al. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112: 2687–2693.
24. Geisler C. Kolstad A. Laurell A. Jerkeman M. Raty R. Andersen N. et al. (2012) Nordic MCL 2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158: 352–362.
25. Geisler C. Kolstad A. Laurell A. Räty R. Jerkeman M. Eriksson M. et al. (2010) The mantle cell lymphoma international prognostic index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115: 1530–1533.
26. Gill S. Herbert K. Prince H. Wolf M. Wirth A. Ryan G. et al. (2009) Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 147: 83–88.
27. Gill S. Hicks R. Seymour J. (2008 a) What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma? Leuk Lymphoma 49: 1653–1656.
28. Gill S. Wolf M. Prince H. Januszewicz H. Ritchie D. Hicks R. et al. (2008 b) [18F] fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 8: 159–165.
29. Gopal A. Kahl B. de Vos S. Wagner-Johnston N. Schuster S. Jurczak W. et al. (2014) PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370: 1008–1018.
30. Goy A. Bernstein S. Kahl B. Djulbegovic B. Robertson M. de Vos S. et al. (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20: 520–525.
31. Goy A. Sinha R. Williams M. Kalayoglu Besisik S. Drach J. Ramchandren R. et al. (2013) Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 31: 3688–3695.
32. Habermann T. Lossos I. Justice G. Vose J. Wiernik P. McBride K. et al. (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Hematol 145: 344–349.
33. Hamadani M. Saber W. Ahn K. Carreras J. Cairo M. Fenske T. et al. (2013) Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the CIBMTR. Biol Blood Marrow Transplant 19: 625–631.
34. Hermine O. Hoster E. Waleski J. Ribrag V. Brousse N. Thieblemont C. et al. (2012) Alternating courses of 3xCHOP and 3xDHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCLnet). Blood (ASH Annual Meeting Abstracts) 623: 151.
35. Hertzberg M. Grigg A. Gottlieb D. Szer J. Roberts A. Hoyt R. et al. (2006) Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant 37: 923–928.
36. Hess G. Herbrecht R. Romaguera J. Verhoef G. Crump M. Gisselbrecht C. et al. (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822–3829.
37. Hill B. Rybicki L. Smith S. Dean R. Kalaycio M. Pohlman B. et al. (2011) Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk and Lymphoma 52: 986–993.
38. Hoster E. Dreyling M. Klapper W. Gisselbrecht C. van Hoof A. Kluin-Nelemans H. et al. (2008) A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 111: 558–565.
39. Inwards D. Fishkin P. Hillman D. Brown D. Ansell S. Kurtin P. et al. (2008) Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 113: 108–116.
40. Kahl B. Spurgeon S. Furman R. Flinn I. Coutre S. Brown J. et al. (2014) A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed / refractory mantle cell lymphoma (MCL) Blood 123: 3398–3405.
41. Kane R. Dagher R. Farrell A. Ko C. Sridhara R. Justice R. et al. (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13: 5291–5294.
42. Karam M. Ata A. Irish K. Feustel P. Mottaghy F. Stroobants S. et al. (2009) FDG positron emission tomography / computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun 30: 770–778.
43. Katzenberger T. Petzoldt C. Holler S. Mäder U. Kalla J. Adam P. et al. (2006) The Ki 67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 107: 3407.
44. Kenkre V. Long W. Eickhoff J. Blank J. McFarland T. Bottner W. et al. (2011) Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 52: 1675–1680.
45. Ketterer N. Salles G. Espinouse D. Dumontet C. Neidhardt-Berard E. Moullet I. et al. (1997) Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 8: 701–704.
46. Khouri I. Lee M. Saliba R. Jun G. Fayad L. Younes A. et al. (2003) Nonablative allogeneic stemcell transplantation for advanced / recurrent mantle-cell lymphoma. J Clin Oncol 21: 4407–4412.
47. Khouri I. Romaguera J. Kantarjian H. Palmer J. Pugh W. Korbling M. et al. (1998) Hyper-CVAD and high dose methotrexate / cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16: 3803–3809.
48. Klapper W. Hoster E. Determann O. Oschlies I. van der Laak J. Berger F. et al. (2009) Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2: 103–111.
49. Kluin-Nelemans H. Hoster E. Hermine O. Walewski J. Trneny M. Geisler C. et al. (2012) Treatment of older patients with mantle cell lymphoma. New Engl J Med 367: 520–531.
50. Le Gouill S. Kroger N. Dhedin N. Nagler A. Bouabdallah K. Yakoub-Agha I. et al. (2012) Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed / refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23: 2695–2703.
51. LeCase A. Vandergrift J. Rodriguez M. Abel G. Crosby A. Czuczman M. et al. (2012) Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis form the NCCN NHL Database. Blood 119: 2093–2099.
52. Lefrere F. Delmer A. Levy V. Delarue R. Varet B. Hermine O. et al. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89: 1275–1276.
53. Lenz G. Dreyling M. Hoster E. Wörmann B. Dührsen U. Metzner B. et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma: results from a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984–1992.
54. Leonard J. LaCasce A. Smith M. Noy A. Chirieac L. Rodig S. et al. (2012) Selective CDK4/6 inhibition with tumor responses by PD 0332991 in patients with mantle cell lymphoma. Blood 119: 4597–4607.
55. Majlis A. Pugh W. Rodriguez M. Benedict W. Cabanillas F. et al. (1997) Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 15: 1664–1671.
56. Maris M. Sandmaier B. Storer B. Chauncey T. Stuart M. Maziarz R. et al. (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104: 3535–3542.
57. Martin P. Leonard J. (2011) Is there a role for “watch and wait” in patients with mantle cell lymphoma? Semin Hematol 48: 189–193.
58. Martin P. Chadburn A. Christos P. Weil K. Furman R. Ruan J. et al. (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27: 1209–1213.
59. Mato A. Svoboda J. Feldman T. Zielonka T. Agress H. Panush D. et al. (2012) Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 118: 3565–3570.
60. Mozos A. Royo C. Hartmann E. de Jong D. Baró C. Valera A. et al. (2009) SOX 11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94: 1555–1562.
61. Norton A. Matthews J. Pappa V. Shamash J. Love S. Rohatiner A. et al. (1995) Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6: 249–256.
62. Nygren L. Wennerholm S. Klimkowska M. Christensson B. Kimby E. Sander B. et al. (2012) Prognostic role of SOX 11 in a population-based cohort of mantle cell lymphoma. Blood 119: 4215–4223.
63. O'Connor O. Wright J. Moskowitz C. Muzzy J. MacGregor-Cortelli B. Stubblefield M. et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676–684.
64. Richard P. Vassallo J. Valmary S. Missoury R. Delsol G. Brousset P. et al. (2006) “In situ-like” mantle cell lymphoma: a report of two cases”. J Clin Pathol 59: 995–996.
65. Romaguera J. Fayad L. Feng L. Hartig K. Weaver P. Rodriguez M. et al. (2010) Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate / cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell Lymphoma. Br J Haematol 150: 200–208.
66. Romaguera J. Fayad L. Rodriguez M. Broglio K. Hagemeister F. Pro B. et al. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23: 7013–7023.
67. Romaguera J. Khouri I. Kantarjian H. Hagemeister F. Rodriguez M. McLaughlin P. et al. (2000) Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39: 77–85.
68. Romaguera J. Medeiros L. Hagemeister F. Fayad L. Rodriguez M. Pro B. et al. (2003) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97: 586–591.
69. Rosenwald A. Wright G. Wiestner A. Chan W. Connors J. Campo E. et al. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185–197.
70. Rummel M. Al-Batran S. Kim S. Welslau M. Hecker R. Kofahl-Krause D. et al. (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23: 3383–3389.
71. Rummel M. Niederle N. Maschmeyer G. Banat G. von Grünhagen U. Losem C. et al. (2013) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment for patients with indolent and mantle cell lymphomas (MCL): an open-label, multicenter, randomised, phase 3 non-inferiority trial. Lancet 381: 1203–1210.
72. Sahakian E. Shah B. Powers J. Deng S. Merino O. Gill A. et al. (2011) The opposing role of histone deacetylase 10 (HDAC10) and HDAC 11 in proliferation / survival of mantle cell lymphoma and chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 118: 1363a.
73. Schaffel R. Moskowitz C. Maragulia J. Portlock C. Hedvat C. Zelenetz A. (2009) Prognostic significance of positron emission tomography (FDG-PET) at baseline and after 4 cycles of R-CHOP in 75 patients with mantle cell lymphoma treated with intensive chemotherapy and autologous stem cell rescue. Blood (ASH Annual Meeting Abstracts) 114: 1226.
74. Spurgeon S. Pindyck T. Okada C. Chen Y. Chen Z. Mater E. et al. (2011) Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 52: 1488–1494.
75. Tam C. Bassett R. Ledesma C. Korbling M. Alousi A. Hosing C. et al. (2009) Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113: 4144–4152.
76. Tiemann M. Schrader C. Klapper W. Dreyling N. Campo E. Norton A. et al. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Hematol 131: 29–38.
77. Vandenberghe E. Ruiz de Elvira C. Loberiza F. Conde E. López-Guillermo A. Gisselbrecht C. et al. (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120: 793–800.
78. Vose J. Bierman P. Weisenberger D. Lynch J. Bociek Y. Chan W. et al. (2000) Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6: 640–645.
79. Wang M. Fayad L. Wagner-Bartak N. Zhang L. Hagemeister F. Neelapu S. et al. (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1 / 2 clinical trial. Lancet Oncol 13: 716–723.
80. Wang M. Gordon L. Rule S. Goy A. Hermine O. Rizo A. et al. (2013 b) A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). J Clin Oncol 31(Suppl.): abstract TPS8613.
81. Wang M. Rule S. Martin P. Goy A. Auer R. Kahl B. et al. (2013 a) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507–516.
82. Younes A. Thieblemont C. Morschhauser F. Flinn I. Friedberg J. Amorim S. et al. (2014) Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomized, phase 1b study. Lancet Oncol 15: 1019–1026.